Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome
- PMID: 34970669
- PMCID: PMC9340985
- DOI: 10.1093/advances/nmab141
Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome
Abstract
Polycystic ovary syndrome (PCOS) affects 1 in 5 women of reproductive age, and is characterized by menstrual irregularities, clinical or biochemical hyperandrogenism, and the presence of polycystic ovary morphology. One of the recommended treatment strategies in the international evidence-based guidelines is lifestyle modification, which includes diet and exercise, with the aim of improving a range of health outcomes. The incurable nature of PCOS reinforces the importance of developing novel and innovative symptomatic relief strategies, which are currently the only available approaches for improving quality of life for these women. Women with PCOS tend to be nutrient deficient in many common vitamins and minerals, thought to be associated with the psychological (depression, anxiety, etc.) and physiological (insulin resistance, diabetes, infertility, etc.) sequelae of the condition. Nutrient supplementation and the integration of complementary medicine as adjuncts to traditional lifestyle-based therapies in PCOS could therefore provide additional benefits to these women. In this review, we synthesize the evidence regarding nutrient supplementation and complementary therapies in PCOS, predominantly from randomized controlled trials, systematic reviews, and meta-analyses, to provide an overview of the state of knowledge in this field. The evidence to date suggests that specific vitamins (B-12, inositols, folate, vitamins D, E, and K), vitamin-like nutrients (bioflavonoids and α-lipoic acid), minerals (calcium, zinc, selenium, and chromium picolinate), and other formulations (melatonin, ω-3 fatty acids, probiotics, and cinnamon), as well as some complementary approaches such as acupuncture and yoga may be beneficial in PCOS. However, there remain areas of uncertainty and key limitations in the literature that must be overcome before these therapies can be integrated into routine clinical practice.
Keywords: PCOS; complementary medicine; diet; minerals; nutraceutical; nutrition; polycystic ovary syndrome; review; supplementation; vitamins.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
Figures

Similar articles
-
Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome.Hum Reprod Update. 2019 Mar 1;25(2):243-256. doi: 10.1093/humupd/dmy045. Hum Reprod Update. 2019. PMID: 30608609
-
Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity.BMC Endocr Disord. 2023 Jan 16;23(1):14. doi: 10.1186/s12902-022-01208-y. BMC Endocr Disord. 2023. PMID: 36647089 Free PMC article. Review.
-
Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.J Obstet Gynaecol. 2020 Jan;40(1):96-101. doi: 10.1080/01443615.2019.1604644. Epub 2019 Jul 24. J Obstet Gynaecol. 2020. PMID: 31339394
-
Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature.Gynecol Endocrinol. 2022 Aug;38(8):623-631. doi: 10.1080/09513590.2022.2089106. Epub 2022 Jun 17. Gynecol Endocrinol. 2022. PMID: 35713558
-
The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: A critical review.J Turk Ger Gynecol Assoc. 2018 Nov 15;19(4):220-232. doi: 10.4274/jtgga.2018.0077. Epub 2018 Oct 9. J Turk Ger Gynecol Assoc. 2018. PMID: 30299265 Free PMC article.
Cited by
-
Causal relationship between fertility nutrients supplementation and PCOS risk: a Mendelian randomization study.Front Endocrinol (Lausanne). 2024 Sep 24;15:1420004. doi: 10.3389/fendo.2024.1420004. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39381438 Free PMC article.
-
n-3 PUFA Promotes Ferroptosis in PCOS GCs by Inhibiting YAP1 through Activation of the Hippo Pathway.Nutrients. 2023 Apr 16;15(8):1927. doi: 10.3390/nu15081927. Nutrients. 2023. PMID: 37111146 Free PMC article.
-
Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention.Inflammopharmacology. 2025 Feb;33(2):431-441. doi: 10.1007/s10787-024-01613-w. Epub 2024 Dec 10. Inflammopharmacology. 2025. PMID: 39656417 Review.
-
Use of traditional and complementary medicine by ethnic Indian women living with polycystic ovary syndrome: a global survey.BMC Complement Med Ther. 2023 Nov 3;23(1):392. doi: 10.1186/s12906-023-04229-9. BMC Complement Med Ther. 2023. PMID: 37924068 Free PMC article.
-
Research trend and hotspots of polycystic ovary syndrome with depression from 1993 to 2024: a bibliometric analysis.Front Glob Womens Health. 2024 Nov 28;5:1468471. doi: 10.3389/fgwh.2024.1468471. eCollection 2024. Front Glob Womens Health. 2024. PMID: 39669109 Free PMC article.
References
-
- Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929–35. - PubMed
-
- Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. - PubMed
-
- Teede HJ, Misso ML, Boyle JA, Garad RM, McAllister V, Downes L, Gibson M, Hart RJ, Rombauts L, Moran Let al. . Translation and implementation of the Australian-led PCOS guideline: clinical summary and translation resources from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Med J Aust. 2018;209(S7):S3–S8. - PubMed